GPC3 and neoplasm: At Day 7 post‐tumour implantation, the tumour size reached the therapeutic window of 50–100 mm3, and 5 × 106 anti‐GPC3 (9F2) CAR‐T cells were administered either intravenously via the tail vein (t.v.)or intratumourally (i.t.)into the tumour xenografts (Figure 1E, red arrow).